ABELES JOHN H

Form 4

December 18, 2009

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

30(h) of the Investment Company Act of 1940

**OMB APPROVAL** OMB

3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or Form 5

Check this box

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

1(b).

Common

Stock

12/17/2009

(Print or Type Responses)

See Instruction

1. Name and A ABELES JO	Address of Reporting Perso OHN H	Symbol	Ticker or Trading	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) 2365 NW 4	(First) (Middle	3. Date of Earliest To (Month/Day/Year) 12/16/2009	ransaction	_X_ Director 10% Own Officer (give title below) below)		
(Street)		4. If Amendment, Da	ate Original	6. Individual or Joint/Group Filing(Check		
DOGA DAS	FON EV 22.424	Filed(Month/Day/Year	r)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting	ng	
BOCA RA	ΓON, FL 33431			Person		
(City)	(State) (Zip)	Table I - Non-I	Derivative Securities Ac	uired, Disposed of, or Beneficially O	wned	
1.Title of Security (Instr. 3)	any		4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or Amount (D) Price	Securities Ownership Ind Beneficially Form: Direct Ber Owned (D) or Ow	Nature of lirect neficial vnership str. 4)	
Common Stock	12/16/2009	P	\$ 1.256 \(\frac{(1)}{2}\)	5 / 000 ( <sup>2</sup> )	orthlea rtners,	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

P

20,000 A

1.298

(3)

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)

77,000 (2)

Ι

Ltd. By Northlea

Ltd.

Partners,

#### Edgar Filing: ABELES JOHN H - Form 4

required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	onNumber	Expiration D	ate	Amour	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underl	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Own
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									A		
									Amount		
						Date	Expiration		or		
						Exercisable	Date		Number		
				G 1 17	(A) (D)				of		
				Code V	(A) (D)				Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
ABELES JOHN H						
2365 NW 41ST STREET	X					

## **Signatures**

BOCA RATON, FL 33431

/s/ Nanette W. Mantell, Attorney-In-Fact for John H.
Abeles
12/18/2009

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.2475 to \$1.26, inclusive. The reporting person undertakes to provide to DUSA Pharmaceuticals, Inc., any security holder of DUSA Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- (2) Includes Stock Awards which vest at the rate of one-quarter of the total grant on each of the first, second, third and fourth anniversaries of the date of the grant.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.259 to \$1.34, inclusive. The reporting person undertakes to provide to DUSA Pharmaceuticals, Inc., any security holder of DUSA Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.

Reporting Owners 2

### Edgar Filing: ABELES JOHN H - Form 4

#### **Remarks:**

Exhibit 24 - Power of Attorney attached

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.